Pasipanodya JG, Gumbo T. Clinical and toxicodynamic evidence that high dose pyrazinamide is not more hepatotoxic than current low doses. Antimicrob Agents Chemother. 2010 May 3.

Deshpande D, Srivastava S, Meek C, Leff R, Hall GS, Gumbo T. Moxifloxacin Pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. Antimicrob Agents Chemother. 2010 Jun;54(6):2534-9.

Shaw JET, Pasipanodya JG, Gumbo T. Meningeal tuberculosis has very poor long term mortality despite standard therapy. Medicine (Baltimore) 2010; 89 (3): 189-95.

Deshpande D, Srivastava S, Meek C, Leff R, Gumbo T. Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification By Use of A Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium avium. Antimicrob Agents Chemother. 2010 May;54(5):1728-33.

Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis. 2010 Apr 15;201(8):1225-31.

Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother. 2010 Apr;54(4):1484-91.

Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009 Dec;29(12):1468-81. Review.

Gumbo T, Dona CS, Meek C, Leff R. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother. 2009 Aug;53(8):3197-204. Epub 2009 May 18.

Gumbo T, Hiemenz J, Ma L, Keirns JJ, Buell DN, Drusano GL. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis. 2008;60(3):329-31.

Sabol K, Gumbo T. Anidulafungin in the treatment of invasive fungal infections. Ther Clin Risk Manag. 2008;4(1):71-8.

Gumbo T. Integrating pharmacokinetics, pharmacodynamics and pharmacogenomics to predict outcomes in antibacterial therapy. Curr Opin Drug Discov Devel. 2008;11(1):32-42

Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother. 2007;51(11):3781-8.

Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, Drusano GL. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.Antimicrob Agents Chemother. 2007;51(7):2329-36.

Gumbo T. Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies. Curr Opin Infect Dis. 2007;20(6):587-91.

Gumbo T, Drusano GL, Liu W, Kulawy RW, Fregeau C, Hsu V, Louie A. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother. 2007;51(3):968-74.

Gumbo T, Louie A, Liu W, Ambrose PG, Bhavnani SM, Brown D, Drusano GL. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis. 2007;195(2):194-201.

Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis. 2007;44(1):79-86.

Gumbo T, Drusano GL, Liu W, Ma L, Deziel MR, Drusano MF, Louie A. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother. 2006;50(11):3695-700

Drusano GL, Louie A, Deziel M, Gumbo T. The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. Clin Infect Dis. 2006;42(4):525-32

Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother. 2005;49(12):5058-68.

Gumbo T, Louie A, Deziel MR, Drusano GL. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob Agents Chemother. 2005;49(8):3178-81.

Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis. 2004;190(9):1642-51.

Moyo VM, Gumbo T. AIDS orphans. N Engl J Med. 2002;347 (18):1455-6

Gumbo T, Chermaly R, Isada CM, Hall G, Gordon S. Late complications of Candida (Torulopsis) glabrata fungemia: description of a phenomenon. Scandinavian Journal of Infectious Diseases. 2002; 34 (11): 817-8.

Gumbo T, Kadzirange G, Mielke J, Gangaidzo IT, Hakim JG. Cryptococcus neoformans meningoencephalitis in African children with AIDS. Pediatric Infectious Disease Journal. 2002; 21: 1: 54-6.

Gumbo T, Just-NĂ¼bling G, Robertson V, Latif AS, Borok MZ, Hohle R. Clinicopathological features of cutaneous histoplasmosis in human immunodeficiency virus-infected patients in  Zimbabwe. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2001; 95: 635-6.

Gwavava C, Chihota V N, Gangaidzo IT, Gumbo T. Dysentery in human immunodeficiency virus infected patients in Zimbabwe: an emerging role for Schistosoma mansoni and Escherichia coli O157?  Annals of Tropical Medicine and Parasitology. 2001; 95:419-23.

Gumbo T, Taege AJ, Mawhorter S, McHenry MS, Lytle BH, Cosgrove DM, Gordon SM. Aspergillus valve endocarditis in patients without prior cardiac surgery. MEDICINE (Baltimore). 2000; (79): 261-8.

Gumbo T, Gangaidzo IT, Sarbah S, Carville A, Tzipori S, Wiest PM. Enterocytozoon bieneusi infection in patients without evidence of  immunosuppression: two cases  from Zimbabwe found to have positive stools by PCR. Annals of Tropical Medicine and  Parasitology  2000; 94 (7); 699-702.

Gumbo T, Sarbah S, Gangaidzo I, Ortega Y, Sterling CR, Carville A, Tzipori S, Wiest PM. Intestinal parasites in patients with diarrhea and human immunodeficiency virus in Zimbabwe. AIDS 1999; 13 (7): 819-821.

Gumbo T, Hobbs R, Carlyn C, Isada CM. Microsporidia in transplant patients.   Transplantation 1999; 67 (3): 482-484.

Gumbo T, Isada CM, Hall G, Karafa M, Gordon SM. Candida glabrata fungemia: Clinical features of 139 patients.  MEDICINE (Baltimore) 1999; 78 (4): 220-227.

Carville A, Mansfield K, Widmer G, Lackner A, Kotler D, Wiest P, Gumbo T, Sarbah S, Tzipori S. Development and application of genetic probes for detection of Enterocytozoon  bieneusi in formalin-fixed stools and in intestinal biopsy specimens from infected patients.  Clinical and Diagnostic Laboratory  Immunology 1997; 4:405-408.